PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023.
Recent Business Highlights
“I am thrilled to announce another record revenue quarter and fiscal year for ProSomnus, as we establish the ProSomnus EVO® precision intraoral technology as a truly differentiated therapy for Obstructive Sleep Apnea,” said Len Liptak, Chief Executive Officer. “The team worked tremendously towards executing on our strategic deliverables, and achieved a record number of procedures in both Q4 and the full year. 2023 was an impactful year, as we continued to generate and share strong clinical data supporting the use of ProSomnus precision oral appliance therapy as a first line therapy for Obstructive Sleep Apnea, advanced enrollment in the Severe Obstructive Sleep Apnea study, and prepared a robust dossier to support a premarket submission to the FDA earlier this year for label expansion to include severe OSA. We continued to fine-tune our operations in an effort to progress towards cash flow breakeven while maintaining strong top line growth. In all, it was a tremendous year of achievements as we advance our mission to position ProSomnus as the leading non-CPAP therapy for Obstructive Sleep Apnea. I am proud of the 2023 results, and I look forward to building upon this momentum during 2024.”
Financial Results for the Fourth Quarter and Year Ended December 31, 2023
Revenues increased to $7.8 million for the fourth quarter ended December 31, 2023. This reflects an increase of $0.8 million, or 11%, and $2.0 million, or 35%, compared to the quarters ended September 2023 and December 2022, respectively. Revenue for the full year 2023 increased to $27.7 million, an increase of $8.3 million, or 43%, compared to the year ended December 31, 2022. This increase was primarily driven by increased adoption of our precision devices, increased sales and marketing investments, and mix shift to the EVO Product, all of which contributed to increased unit volumes.
Cost of revenue totaled $4.1 million for the fourth quarter ended December 31, 2023, representing 53% of revenue. This reflects an increase of $0.6 million, or 15%, and $1.4 million, or 54%, compared to the quarters ended September 2023 and December 2022, respectively. For the full year 2023 cost of revenue totaled $13.6 million, representing 49% of revenue, an increase of $4.5 million, or 49%, compared to $9.1 million, or 47% of revenue, for the year ended December 31, 2022. The increase was primarily due to product costs associated with higher sales volume of our devices and increased overhead stemming from our move into our new manufacturing facility during early 2023.
Sales and marketing expenses totaled $3.4 million for the fourth quarter ended December 31, 2023. Relative to the quarter ended June 30, 2023, the commencement of our expense reduction initiative, sales and marketing has decreased 6% and as percentage of revenue has decreased from 53% to 43% for the quarters ended December 31, 2023 and June 30, 2023, respectively. Fourth quarter 2023 sales and marketing expense reflects a modest increase compared to the quarter ended September 2023, and an increase of $1.0 million, or 40%, compared to the quarter ended December 2022. Sales and marketing expenses for the full year 2023 totaled $13.1 million, an increase of $4.2 million, or 48%, compared to the year ended December 31, 2022. This year-over-year increase reflects an increase in personnel and consulting-related expenses of $2.7 million due to expansion of the sales team during mid-2023, distribution, marketing events, and advertising expenses of $1.2 million, and commissions paid on higher revenues.
General and administrative expenses totaled $4.0 million for the quarter ended December 31, 2023. Relative to the quarter ended June 30, 2023, general and administrative expenses decreased 11% and as percentage of revenue has decreased from 65% to 51% for the quarters ended December 31, 2023 and June 30, 2023, respectively. Fourth quarter 2023 general and administrative expenses reflect an increase of $0.5 million, or 16%, compared to the quarter ended September 2023, and a decrease of $1.7 million, or 30%, compared to the quarter ended December 2022. For the full year 2023 general and administrative expenses totaled $15.2 million, an increase of $5.3 million, or 54%, compared to $9.9 million for the year ended December 31, 2022. This increase was driven primarily by $2.9 million increase in costs that scale with top line and production growth including credit card fees, utilities, rent and depreciation associated with the new manufacturing facility, and public company expenses including $2.5 million increase in professional services, $1.3 million increase in personnel costs, and $1.0 million in insurance, partially offset by $1.4 million decrease in stock-based compensation.
Research and development expenses totaled $1.4 million for the quarter ended December 31, 2023. Relative to the quarter ended June 30, 2023, the commencement of our expense reduction initiative, research and development expenses remained consistent and as percentage of revenue has decreased from 20% to 17% for the quarters ended December 31, 2023 and June 30, 2023, respectively. Fourth quarter 2023 reflects an increase of $0.3 million, or 31.4%, and $0.3 million, or 28% compared to the quarters ended September 2023 and December 2022, respectively. For the full year 2023 research and development expenses totaled $4.8 million, an increase of $1.8 million, or 61%, compared to the year ended December 31, 2022. This increase was primarily driven by an increase in expenses associated with the ongoing development of the RPMO2, the Front Line OSA Therapy (“FLOSAT”) clinical study and costs associated with preparing the 510(k) Premarket Notification to U.S. Food and Drug Administration for the severe indication label expansion.
Other income (expense) is comprised of interest expense and accounting charges associated with changes in fair values of certain assets and liabilities and charges associated with financings and debt restructuring. Total other expense for the year ended December 31, 2023 aggregated to $5.0 million compared to total other income of $4.3 million for the year ended December 31, 2022. The other income resulting from the valuation changes in certain of our liabilities reflect the price decline of our publicly traded stock which is a significant input into the fair value valuation assumptions for the liabilities revalued. This other income was offset during 2023 by a loss on debt restructuring associated with changes in the terms of certain of our senior and subordinate indentures as part of our September 2023 financing transactions. Interest expense reflects the interest on our senior and subordinate indentures and equipment financing liabilities.
Cash and restricted cash at December 31, 2023 totaled $7.1M, reflecting a decrease of $4.9 million from the $12.0 million reported at September 30, 2023. The decrease noted includes approximately $1.0 million of cash used to renew the Company’s insurance policies during December 2023.
Conference Call and Webcast Information
Interested parties may register for the conference call at 1:30 pm PT / 4:30 pm ET, today March 26, 2024 using the following link: OSA Q4 2024 Financial Results Call. Alternatively, you may access the live webcast of the conference call by using the following link: OSA Q4 2024 Webcast. The links will also be posted in the Investor Relations section of the ProSomnus website at News & Events.
About ProSomnus
ProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide, that is associated with comorbidities including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. To learn more, visit www.ProSomnus.com.
Important Notice Regarding Forward-Looking Statements
This Press Release contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the Company’s review of potential financing and strategic alternatives, the Company’s research and development efforts, the Company’s prospects for 2024, the Company’s mission of becoming the leader non-CPAP therapy for Obstructive Sleep Apnea and the Company’s ability to fine tune its operations, are forward-looking statements. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements, although not all forward-looking statements contain these or similar identifying words.
These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated. Such risks and uncertainties include, but are not limited to: ProSomnus’s ability to continue as a going concern; ProSomnus’s ability raise additional capital to fund its business on acceptable terms or at all; ProSomnus’s ability to regain compliance with the covenants under its convertible notes; ProSomnus’s ability to negotiate and consummate a financing or other strategic transaction; changes in the competitive industries in which the Company operates and variations in operating performance across competitors; changes in laws and regulations affecting ProSomnus’s business; the risk of downturns in the market and ProSomnus’s industry; risks related to the uncertainty of the projected financial information with respect to ProSomnus; risks related to ProSomnus’s limited operating history and history of losses; the timing of expected business milestones; ProSomnus’s ability to implement its business plan and scale its business, which includes the recruitment of healthcare professionals to prescribe and dentists to deliver ProSomnus oral devices; the understanding and adoption by dentists and other healthcare professionals of ProSomnus oral devices for mild-to-moderate OSA; expectations concerning the effectiveness of OSA treatment using ProSomnus oral devices and the potential for patient relapse after completion of treatment; the potential financial benefits to dentists and other healthcare professionals from treating patients with ProSomnus oral devices and using ProSomnus’s monitoring tools; ProSomnus’s potential profit margin from sales of ProSomnus oral devices; ProSomnus’s ability to properly train dentists in the use of the ProSomnus oral devices and other services it offers in their dental practices; ProSomnus’s ability to formulate, implement and modify as necessary effective sales, marketing, and strategic initiatives to drive revenue growth; ProSomnus’s ability to expand internationally; the viability of ProSomnus’s intellectual property and intellectual property created in the future; acceptance by the marketplace of the products and services that ProSomnus markets; government regulations and ProSomnus’s ability to obtain applicable regulatory approvals and comply with government regulations, including under healthcare laws and the rules and regulations of the U.S. Food and Drug Administration; the extent of patient reimbursement by medical insurance in the United States and internationally; and the outcome of any legal proceedings that may be instituted against the Company. A further list and description of risks and uncertainties can be found in the most recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
| PROSOMNUS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands) | |||||||||||||||||||||||||
| Three Month Period Ended | Three Month Period Ended | ||||||||||||||||||||||||
| December 31 | September 30 | December 31 | December 31, 2023 vs. | December 31, | |||||||||||||||||||||
| 2023 | 2023 | 2022 | September 30, 2023 | 2022 vs 2023 | |||||||||||||||||||||
| ($) | (%) | ($) | (%) | ||||||||||||||||||||||
| Revenue | $ | 7,838 | $ | 7,071 | $ | 5,792 | $ | 767 | 10.8 | % | $ | 2,046 | 35.3 | % | |||||||||||
| Operating expenses | |||||||||||||||||||||||||
| Cost of revenue | 4,133 | 3,580 | 2,687 | 553 | 15.4 | % | 1,446 | 53.8 | % | ||||||||||||||||
| Sales and marketing | 3,378 | 3,240 | 2,415 | 138 | 4.3 | % | 963 | 39.9 | % | ||||||||||||||||
| Research and development | 1,367 | 1,040 | 1,065 | 327 | 31.4 | % | 302 | 28.4 | % | ||||||||||||||||
| General and administrative | 3,970 | 3,427 | 5,675 | 543 | 15.8 | % | (1,705 | ) | -30.0 | % | |||||||||||||||
| Total operating expenses | 12,848 | 11,287 | 11,842 | 1,561 | 13.8 | % | 1,006 | 8.5 | % | ||||||||||||||||
| Loss from operations | (5,010 | ) | (4,216 | ) | (6,050 | ) | (794 | ) | 18.8 | % | 1,040 | -17.2 | % | ||||||||||||
| Other income (expense) | |||||||||||||||||||||||||
| Interest expense | (1,481 | ) | (1,489 | ) | (2,405 | ) | 8 | -0.5 | % | 924 | -38.4 | % | |||||||||||||
| Change in fair value of earnout liability | 110 | 3,880 | 9,260 | (3,770 | ) | -97.2 | % | (9,150 | ) | -98.8 | % | ||||||||||||||
| Change in fair value of debt | 258 | 3,700 | 553 | (3,442 | ) | -93.0 | % | (295 | ) | -53.3 | % | ||||||||||||||
| Change in fair value of warrant liability | 39 | 593 | 3,255 | (554 | ) | -93.4 | % | (3,216 | ) | -98.8 | % | ||||||||||||||
| Loss on extinguishment of debt | (707 | ) | (9,743 | ) | (2,405 | ) | 9,036 | -92.7 | % | 1,698 | -70.6 | % | |||||||||||||
| Other | (78 | ) | (3,964 | ) | - | 3,886 | -98.0 | % | (78 | ) | - | ||||||||||||||
| Total other income (expense) | (1,859 | ) | (7,023 | ) | 8,258 | 5,164 | -73.5 | % | (10,117 | ) | -122.5 | % | |||||||||||||
| Net loss | $ | (6,869 | ) | $ | (11,239 | ) | $ | 2,208 | $ | 4,370 | -38.9 | % | $ | (9,077 | ) | -411.1 | % | ||||||||
| Year Ended | Year Ended | ||||||||||||||
| December 31 | December 31 | December 31, | |||||||||||||
| 2023 | 2022 | 2022 vs 2023 | |||||||||||||
| ($) | (%) | ||||||||||||||
| Revenue | $ | 27,652 | $ | 19,393 | $ | 8,259 | 42.6 | % | |||||||
| Operating expenses | |||||||||||||||
| Cost of revenue | 13,641 | 9,127 | 4,514 | 49 | % | ||||||||||
| Sales and marketing | 13,085 | 8,865 | 4,220 | 47.6 | % | ||||||||||
| Research and development | 4,802 | 2,981 | 1,821 | 61.1 | % | ||||||||||
| General and administrative | 15,230 | 9,895 | 5,335 | 53.9 | % | ||||||||||
| Total operating expenses | 46,758 | 30,868 | 15,890 | 51.5 | % | ||||||||||
| Loss from operations | (19,106 | ) | (11,475 | ) | (7,631 | ) | 66.5 | % | |||||||
| Other income (expense) | |||||||||||||||
| Interest expense | (5,382 | ) | (6,120 | ) | 738 | -12.1 | % | ||||||||
| Change in fair value of earnout liability | 12,190 | 9,260 | 2,930 | 31.6 | % | ||||||||||
| Change in fair value of debt | 1,328 | 553 | 775 | 140.1 | % | ||||||||||
| Change in fair value of warrant liability | 1,896 | 3,235 | (1,339 | ) | -41.4 | % | |||||||||
| Loss on extinguishment of debt | (10,450 | ) | (2,598 | ) | (7,852 | ) | 302.2 | % | |||||||
| Other | (4,571 | ) | - | (4,571 | ) | - | |||||||||
| Total other income (expense) | (4,989 | ) | 4,330 | (9,319 | ) | -215.2 | % | ||||||||
| Net loss | $ | (24,095 | ) | $ | (7,145 | ) | $ | (16,950 | ) | 237.2 | % | ||||
| PROSOMNUS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share data) | ||||||
| December 31, 2023 | December 31, 2022 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash, restricted cash and cash equivalents | $ | 7,063 | $ | 15,916 | ||
| Accounts receivable, net | 3,839 | 2,843 | ||||
| Inventory | 2,039 | 640 | ||||
| Prepaid expenses and other current assets | 1,369 | 1,851 | ||||
| Total current assets | 14,310 | 21,250 | ||||
| Property and equipment, net | 3,358 | 2,404 | ||||
| Finance lease right-of-use assets | 3,265 | 3,650 | ||||
| Operating lease right-of-use assets | 5,069 | 5,633 | ||||
| Other assets | 285 | 263 | ||||
| Total assets | $ | 26,287 | $ | 33,200 | ||
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 4,047 | $ | 2,102 | ||
| Accrued expenses and other current liabilities | 6,756 | 3,706 | ||||
| Equipment financing obligation | 57 | 59 | ||||
| Finance lease liabilities | 1,052 | 1,009 | ||||
| Operating lease liabilities | 304 | 215 | ||||
| Senior Convertible Notes at fair value, current portion | 2,125 | — | ||||
| Total current liabilities | 14,341 | 7,091 | ||||
| Equipment financing obligation, net of current portion | 129 | 186 | ||||
| Finance lease liabilities, net of current portion | 2,009 | 2,081 | ||||
| Operating lease liabilities, net of current portion | 5,221 | 5,526 | ||||
| Senior Convertible Notes at fair value, net of current portion | 12,152 | 13,651 | ||||
| Subordinated Convertible Notes at fair value | 18,320 | 10,356 | ||||
| Earnout and warrant liability | 716 | 14,802 | ||||
| Total liabilities | 52,888 | 53,693 | ||||
| Commitments and contingencies | ||||||
| Redeemable convertible preferred stock: | ||||||
| 11,555 | — | |||||
| Stockholders’ deficit: | ||||||
| Common Stock | 2 | 2 | ||||
| Additional paid-in capital | 196,731 | 190,299 | ||||
| Accumulated deficit | -234,889 | -210,794 | ||||
| Total stockholders’ deficit | -38,156 | -20,493 | ||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ deficit | $ | 26,287 | $ | 33,200 | ||
Investor Contact
Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Heather Whalen
ProSomnus
Phone: +1.925.360.2990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.47 |
| Daily Volume: | 0 |
| Market Cap: | US$8.170M |
March 15, 2024 February 22, 2024 December 19, 2023 November 09, 2023 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
